Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00229684 · ClinicalTrials.gov registry record · Phase 2
ARMOR (Analyzing Renal Mechanisms of Creatinine Excretion in Patients On tesaglitazaR)
A Phase 2 study, sponsored by AstraZeneca.
- Terminated
- Registry status
- Phase 2
- Development phase
- 100
- Enrollment target
NCT00229684 is a Phase 2 study that was terminated before completion, run by AstraZeneca. The registered enrollment target is 100 participants.
The verdict
NCT00229684, a Phase 2 study, was terminated before completion, sponsored by AstraZeneca.
- TERMINATED
- Registry status
- Phase 2
- Development phase
- 100 participants
- Enrollment target
Study Summary
This is a prospective 24-week, randomized, parallel-group, multi-center, active-controlled (pioglitazone 45 mg) open-label study designed to assess the effects of tesaglitazar 2 mg per day on components of renal excretion of creatinine in type 2 diabetics. The study comprises a 2-week enrollment period, followed by a 24-week double blind treatment period and an 8-week follow-up period
Interventions
- DRUG pioglitazone
- DRUG Tesaglitazar
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 100 participants |
| Start Date | 2004-09 |
| Est. Completion | 2006-06 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00229684
The ClinicalTrials.gov registry entry for NCT00229684 describes a study currently listed as terminated, categorized as Phase 2. The registered enrollment target is 100 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is AstraZeneca, which has 1,285 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which pioglitazone is the first listed.
NCT00229684 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00229684 about?
NCT00229684 is a clinical study titled "ARMOR (Analyzing Renal Mechanisms of Creatinine Excretion in Patients On tesaglitazaR)". This is a prospective 24-week, randomized, parallel-group, multi-center, active-controlled (pioglitazone 45 mg) open-label study designed to assess the effects of tesaglitazar 2 mg per day on components of renal excretion of creatinine in type 2 diabetics. The study comprises a 2-week enrollment per...
What is the current status of trial NCT00229684?
This trial is currently terminated. It is a Phase 2 study. The enrollment target is 100 participants. The study started on 2004-09. Estimated completion is 2006-06.
What interventions are being tested in trial NCT00229684?
The interventions under investigation include: pioglitazone (DRUG), Tesaglitazar (DRUG).
Who is sponsoring clinical trial NCT00229684?
This trial is sponsored by AstraZeneca, which has 1,285 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.